Cite

HARVARD Citation

    Meredith, R. et al. (2018). Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab. American journal of clinical oncology. p. . [Online]. 
  
Back to record